Dr. Hamelin, according to OECD data, Canada is the only G7 country to have reduced the share of its gross domestic product spent on research and development between 2001 and 2021, while all our partners increased their investments.
How do you explain a decline of this nature, and what concrete impact has it had on our ability to innovate and maintain a competitive pharmaceutical ecosystem?